Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) (METROS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02499614

Recruitment Status : Unknown

Verified October 2017 by Fondazione Ricerca Traslazionale.
Recruitment status was: Recruiting

First Posted : July 16, 2015

Last Update Posted : October 25, 2017

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Fondazione Ricerca Traslazionale

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 2018
Estimated Study Completion Date :	December 2018

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18.

To Top